Research

Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT): NICHD/1R01HD085993-01

PI: Ann Wu

Applications of the genetic knowledge resulting from the Human Genome Project are not yet available for asthma despite the immense potential that pharmacogenomics demonstrates for improving asthma care. This research will link genetic variants to therapeutic responses with additional information from genomics and metabolomics to provide insight into the biologic pathways that may be activated in an age-dependent method.  This study will elucidate response to the two most commonly used medications for asthma, inhaled steroids and β2-agonists. This research employs existing genetic, genomic, and metabolomics data from clinical trial and real-life populations. The ability to link genetic variants to the therapeutic responses with additional information from genomics and metabolomics will provide insight into the biologic pathways that may be activated.  By integrating and accounting for the interplay between genetics, genomics, and metabolomics, we will develop a comprehensive signature that predicts response to inhaled steroids and β2-agonists.  Knowledge gained from this research will advance the field of personalized medicine for pediatric asthma.

 

Genomics-based Technologies: Access and Reimbursement Issues (funded by NHGRI)

Genomics-based health care is complex, rapidly evolving, and highly relevant to public health because of its potential use in assessing risk, diagnosing disease, and developing treatment plans. Access to genomic tests often depends on cost and coverage of services by the health plan. Drs. Lu and Wu are leading the current investigation to systematically examine access and reimbursement issues relating to guideline-recommended pharmacogenomic tests and implications of barriers to access and/or differential access for patients, providers, and society. Understanding access barriers in current practice and decision-making processes will allow policy makers to develop coverage policies to optimize affordable and equitable access to guideline-recommended genomics-based technologies in order to improve population health.